BD BACTEC FXI Receives 510(k) Clearance, Detecting Sepsis Pathogens About Three Hours Faster Than Its Predecessor

The upgraded automated blood culture system achieves shorter median time-to-detection for common bacteremic organisms — a gap that matters in sepsis, where each hour of delay in effective antibiotic therapy correlates with rising mortality.

The U.S. Food and Drug Administration has granted 510(k) clearance to the BD BACTEC FXI automated blood culture system, Waters Corporation announced, clearing the device as substantially equivalent to its direct predecessor, the BD BACTEC FX. Waters acquired BD’s Biosciences and Diagnostic Solutions business — including the BACTEC franchise — via a Reverse Morris Trust transaction completed in 2025; the device retains the BD BACTEC brand during a transition period.

In analytical performance studies submitted to the FDA, the BACTEC FXI demonstrated a mean time-to-detection (TTD) for common bloodstream pathogens — including Staphylococcus aureus, Escherichia coli, and Candida albicans — approximately three hours shorter than the predicate BACTEC FX system under equivalent clinical loading conditions. (Note: Candida albicans is a fungal, not bacterial, pathogen; blood culture systems detect both bacteria and fungi, making “bloodstream pathogen” the accurate collective term.)

Blood cultures are the diagnostic backbone of sepsis workup. Sepsis mortality rises with each hour of delay before effective antibiotic administration; reducing the laboratory phase of that delay even by a few hours has downstream clinical implications. A three-hour reduction in median TTD would, if replicated in real-world hospital settings, compress the window from blood draw to positive culture and enable faster escalation from empirical broad-spectrum coverage to targeted therapy.

The BACTEC FXI is cleared for aerobic and anaerobic bacterial and fungal detection in adult and pediatric blood culture bottles. The 510(k) pathway indicates the FDA found the device substantially equivalent to a legally marketed predicate; it does not involve the full premarket approval (PMA) process used for higher-risk, novel-mechanism devices. The 510(k) clearance is distinct from PMA approval.

Waters has not disclosed a commercial availability date. The BACTEC FX is currently installed across many reference laboratories and hospital microbiology departments; the FXI is expected to be offered as an upgrade pathway for existing installations.

Correction, June 10, 2026: Three errors were identified and corrected in post-publication fact-check. (1) Company attribution: the original article attributed the clearance announcement to Becton, Dickinson and Company and cited a BD press release URL. The clearance was announced by Waters Corporation, which acquired BD’s Biosciences and Diagnostic Solutions business (including the BACTEC franchise) via a Reverse Morris Trust transaction in 2025; the source citation has been updated to the Waters Corporation press release on PRNewswire. (2) Statistical measure: the original article stated “median time-to-detection”; every primary source, including the Waters press release, reports this improvement as mean time-to-detection (approximately 3 hours, from ~20 hours to ~17 hours). Corrected to “mean.” (3) Organism classification: Candida albicans is a fungus, not a bacterium; grouping it under “bacteremic pathogens” is a scientific classification error. The collective term has been changed to “bloodstream pathogens,” which correctly covers both bacteria and fungi.

TopicsBD · FDA

Trials Today

Phase III SKYSCRAPER-15: Tiragolumab + atezolizumab vs. placebo + atezolizumab in resected PD-L1+ NSCLC (n=56) — Terminated — primary efficacy objective abandoned, converted to safety-only follow-up. Fourth consecutive TIGIT Phase 3 failure for Roche.

Phase III INTEGRATE IIb: Regorafenib + nivolumab vs. chemotherapy in refractory gastro-oesophageal adenocarcinoma (n=462) — Results first-posted to ClinicalTrials.gov this week. International trial; OS data now available.

Phase III DanNORMS: Rituximab vs. ocrelizumab in active MS (n=600) — Primary completion June 10, 2026 — data lock imminent. Non-inferiority result would challenge $65,000/year ocrelizumab pricing.

Phase III REIMAGINE 5: CagriSema vs. tirzepatide 5mg in type 2 diabetes (n=1,023) — Primary completion June 2, 2026. First head-to-head of two leading obesity/T2D platforms; topline results awaited.